- ISIN
- US0717711099
- Sector
- Healthcare
- Industry
- Biotechnology
Highlights
- Market Cap
- $2.06B
- Enterprise Value
- $1.99B
- EPS (TTM)
- DKK 4.97
- PE Ratio
- 11.70
- PEG Ratio
- 0.16
- Total Revenue (TTM)
- DKK 5.66B
- Gross Profit (TTM)
- DKK 2.81B
- EBITDA (TTM)
- DKK 2.25B
- Year Range
- $8.67 - $13.00
- ROA (TTM)
- 8.33%
- ROE (TTM)
- 9.26%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
BVNRY Performance Chart
Bavarian Nordic A/S ADR (BVNRY) is down 10.1% since the beginning of the year. At $9 per share, BVNRY is trading 31.4% below its 52-week high of $13. Investors who bought $1,000 worth of BVNRY shares 5 years ago would now be looking at an investment worth $607.
Loading charts...
Returns By Period
Bavarian Nordic A/S ADR (BVNRY) has returned -10.13% so far this year and -0.04% over the past 12 months. Over the last ten years, BVNRY has returned -2.39% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
Bavarian Nordic A/S ADR
- 1D
- -2.83%
- 1M
- -12.29%
- YTD
- -10.13%
- 6M
- -10.08%
- 1Y
- -0.04%
- 3Y*
- -3.90%
- 5Y*
- -9.51%
- 10Y*
- -2.39%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
BVNRY Monthly Returns History
Based on dividend-adjusted daily data since Feb 18, 2014, BVNRY's average daily return is +0.10%, while the average monthly return is +1.42%. At this rate, an investment would double in approximately 4.1 years.
Historically, 48% of months were positive and 52% were negative. The best month was Oct 2014 with a return of +59.5%, while the worst month was Mar 2020 at -49.6%. The longest winning streak lasted 9 consecutive months, and the longest losing streak was 5 months.
On a daily basis, BVNRY closed higher 30% of trading days. The best single day was May 19, 2022 with a return of +73.3%, while the worst single day was Sep 15, 2017 at -46.4%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 3.06% | 1.05% | -3.99% | -1.46% | -1.23% | -7.66% | -10.13% | ||||||
| 2025 | 4.18% | -14.88% | -6.54% | 9.49% | 9.49% | 1.85% | 35.75% | 2.97% | -2.72% | 2.09% | -22.04% | 4.10% | 14.01% |
| 2024 | -11.95% | -2.60% | -0.93% | -2.49% | 23.26% | -7.50% | 7.75% | 47.64% | -13.09% | -9.08% | -12.36% | -4.33% | -0.45% |
| 2023 | 4.14% | -3.03% | -7.51% | -3.69% | -2.63% | 6.01% | -23.82% | 3.49% | 0.01% | -14.54% | 27.74% | 7.81% | -13.84% |
| 2022 | -19.33% | -12.17% | -12.17% | -12.19% | 36.73% | 10.85% | 48.20% | -24.23% | -22.82% | 8.91% | 5.61% | -8.60% | -24.53% |
| 2021 | 8.47% | 18.18% | 14.95% | -6.19% | 2.69% | -12.19% | 3.40% | 22.91% | 4.46% | -11.08% | 1.14% | -15.94% | 25.12% |
Benchmark Metrics
Bavarian Nordic A/S ADR has an annualized alpha of 19.20%, beta of 0.41, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since February 18, 2014.
- This stock participated in 105.92% of S&P 500 Index downside but only 61.80% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.41 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 19.20%
- Beta
- 0.41
- R²
- 0.01
- Upside Capture
- 61.80%
- Downside Capture
- 105.92%
Return for Risk
Risk / Return Rank
BVNRY ranks 40 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Bavarian Nordic A/S ADR (BVNRY) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BVNRY | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.03 | ||
| Sortino ratioReturn per unit of downside risk | -2.49 | ||
| Omega ratioGain probability vs. loss probability | 1.05 | 1.37 | -0.32 |
| Calmar ratioReturn relative to maximum drawdown | -0.00 | 2.78 | -2.79 |
| Martin ratioReturn relative to average drawdown | -0.00 | 12.44 | -12.44 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Bavarian Nordic A/S ADR. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Bavarian Nordic A/S ADR was 77.80%, occurring on Apr 1, 2020. The portfolio has not yet recovered.
The current Bavarian Nordic A/S ADR drawdown is 60.70%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
COVID crash2020 | -77.80%Apr 2020 | 2y 6mo | — | 8y 9moSep 2017 - now |
2016 bear market2016 | -42.86%Nov 2016 | 1y 7mo | 5mo 4d | 2y 16dApr 2015 - Apr 2017 |
2015 correction2015 | -16.41%Feb 2015 | 27d | 29d | 1mo 26dJan 2015 - Mar 2015 |
2014 pullback2014 | -9.75%Dec 2014 | 1mo 1d | 1mo 5d | 2mo 6dOct 2014 - Jan 2015 |
2015 pullback2015 | -8.85%Mar 2015 | 6d | 8d | 14dMar 2015 - Mar 2015 |
Drawdown Indicators
| BVNRY | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -77.80% | -56.78% | -21.02% |
Max Drawdown (1Y)Largest decline over 1 year | -29.21% | -9.10% | -20.11% |
Max Drawdown (3Y)Largest decline over 3 years | -50.97% | -18.90% | -32.07% |
Max Drawdown (5Y)Largest decline over 5 years | -69.61% | -25.43% | -44.18% |
Max Drawdown (10Y)Largest decline over 10 years | -77.80% | -33.92% | -43.88% |
Current DrawdownCurrent decline from peak | -60.70% | -1.80% | -58.90% |
Average DrawdownAverage peak-to-trough decline | -41.39% | -10.71% | -30.68% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 17.20% | 2.03% | +15.17% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Bavarian Nordic A/S ADR over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Bavarian Nordic A/S ADR is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for BVNRY, comparing it with other companies in the Biotechnology industry. Currently, BVNRY has a P/E ratio of 11.7. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for BVNRY compared to other companies in the Biotechnology industry. BVNRY currently has a PEG ratio of 0.2. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for BVNRY relative to other companies in the Biotechnology industry. Currently, BVNRY has a P/S ratio of 2.4. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for BVNRY in comparison with other companies in the Biotechnology industry. Currently, BVNRY has a P/B value of 1.1. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with BVNRY
Add Bavarian Nordic A/S ADR to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with BVNRY